acalabrutinib,zanubrutinib
beigene,astrazeneca
['acalabrutinib', 'zanubrutinib', 'lymsm']
zanubrutinib demonstrates efficacy and safety in acalabrutinib-intolerant patients with b-cell malignancies #ash22 #lymsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.